Observing Finerenone Use in Adults with Chronic Kidney Disease and Type 2 Diabetes During Routine Medical Care in South Korea The FINE-REAL Korea Study

What this Trial Is About

Researchers are collecting and studying data from adults with chronic kidney disease CKD and type 2 diabetes T2D who are receiving finerenone as part of their routine medical care. CKD is a long-term condition where the kidneys gradually lose their ability to filter waste, and T2D can lead to kidney damage due to high blood sugar levels. The study aims to better understand the characteristics and treatment patterns of people starting finerenone in South Korea. The study observes participants who have recently started or will start finerenone treatment prescribed by their doctor. Finerenone is a medication that blocks proteins which may harm the kidneys and heart. Researchers are collecting information about clinical characteristics, reasons for starting or stopping finerenone, treatment duration and dosing, and other medications taken alongside finerenone. Data will be gathered through medical records and interviews during routine visits. Participants are involved for up to 12 months or until finerenone treatment stops early. The study will monitor any medical problems, including adverse events and high potassium levels hyperkalemia that may require additional care such as dialysis or hospitalization. Researchers will analyze clinical data, treatment patterns, and safety information to better understand finerenone use in this population.

An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South Korea